PubRank

G P Browman

Author PubWeight™ 42.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ 2000 5.43
2 The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995 5.05
3 The Internet and evidence-based decision-making: a needed synergy for efficient knowledge management in health care. CMAJ 2000 3.46
4 A guide to interpreting discordant systematic reviews. CMAJ 1997 2.29
5 Systemic adjuvant therapy for node-negative breast cancer. CMAJ 1989 1.42
6 Science, language, intuition, and the many meanings of quality of life. J Clin Oncol 1999 1.42
7 Scientific evidence and expert opinion in ACP Journal Club: commentary on commentaries. ACP J Club 1994 1.40
8 Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf 2011 1.39
9 The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Blood 1986 1.26
10 A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer 2002 1.24
11 When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991 1.20
12 Development and aftercare of clinical guidelines: the balance between rigor and pragmatism. JAMA 2001 1.16
13 Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol 2001 0.98
14 Searching the medical literature for the best evidence to solve clinical questions. Ann Oncol 1998 0.92
15 Resistance to photodynamic therapy in radiation induced fibrosarcoma-1 and Chinese hamster ovary-multi-drug resistant. Cells in vitro. Photochem Photobiol 1991 0.84
16 Health care professionals' familiarity with non-pharmacological strategies for managing cancer pain. Psychooncology 1999 0.83
17 Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines. Ann Oncol 2002 0.83
18 Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2001 0.83
19 The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992 0.82
20 Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: a prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Leuk Res 1995 0.79
21 A complement independent erythropoietic inhibitor acting on the progenitor cell in refractory anemia. Am J Med 1976 0.79
22 Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care 2001 0.79
23 Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines. Cancer Chemother Pharmacol 1985 0.79
24 Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995 0.79
25 Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 1986 0.78
26 Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines. Chem Biol Interact 1977 0.78
27 Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1983 0.78
28 Chemoprevention for lung cancer--evidence for a high degree of compliance. Cancer Detect Prev 1990 0.77
29 Influence of the poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on macrophage and granulocyte differentiation of HL-60 cells. Am J Hematol 1986 0.76
30 Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leuk Lymphoma 1993 0.76
31 Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap. J Clin Oncol 1986 0.76
32 Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leuk Res 1994 0.75
33 Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage. Biochem Pharmacol 1981 0.75
34 The intracellular mechanism of action of metoprine (DDMP). Eur J Cancer 1980 0.75
35 Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate. Cancer Chemother Pharmacol 1985 0.75
36 Implications of using a prognostic index to select therapy for patients with aggressive histology lymphoma. Can J Oncol 1995 0.75
37 Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate. Biochem Pharmacol 1980 0.75
38 Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence? Cancer Treat Rep 1984 0.75
39 Development of clinical practice guidelines: surgical perspective. World J Surg 1999 0.75
40 Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines. Cancer Treat Rep 1982 0.75
41 Should-alpha-interferon be included as standard treatment in multiple myeloma? Eur J Cancer 1998 0.75
42 Survival results from a phase III study of simultaneous versus 1-hour sequential methotrexate-5-fluorouracil chemotherapy in head and neck cancer. Head Neck Surg 1986 0.75
43 A pilot study of carboplatin augmentation therapy for patients with poor risk acute non-lymphocytic leukemia. Leuk Res 1992 0.75
44 Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report. Cancer Treat Rep 1985 0.75
45 Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside. Br J Haematol 1984 0.75
46 [Tools for the practice of evidence based medicine (I). Update in evidence based information resources for clinical practice]. Med Clin (Barc) 2000 0.75
47 Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo. Cancer Treat Rep 1980 0.75